Bioceros Holding B.V. signs licence agreement with Gen-X for the CHO expression module
Bioceros signed a licence agreement to gain access to Gen-X’s CHO expression module SuRE12-EH. The expression module will be tested internally by Bioceros and used for their cell line development programs if results are satisfactory. The SuRE12-EH expression module was constructed based on a SuRE screen of the CHO genome and shows higher and much more stable expression over prolonged periods than the commonly used CMV promoter.
Gen-X provides functional genome annotation on an unprecedented scale. We use our unique SuRE technology to profile the strength of gene promoters and enhancers for entire genomes of different organisms and under different environmental conditions. These genome-wide profiles allow us to identify tailored promoter and enhancer combinations for usage in recombinant protein production and gene therapy and in addition can serve as maps for CRISPR-Cas9 targeting.